伊克力西斯(EXEL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

EXEL 伊克力西斯

盘后交易 01-14 16:45:51 EST

45.23

+1.15

+2.61%

盘后45.23

+0.000.00%

16:37 EST

最高45.34	最低44.02	成交量170.56万
今开44.28	昨收44.08	日振幅2.98%
总市值121.27亿	流通市值104.86亿	总股本2.68亿
成交额7,664万	换手率0.74%	流通股本2.32亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"EXEL","market":"US","secType":"STK","nameCN":"伊克力西斯","latestPrice":45.23,"timestamp":1768424400000,"preClose":44.08,"halted":0,"volume":1705568,"hourTrading":{"tag":"盘后","latestPrice":45.23,"preClose":45.23,"latestTime":"16:37 EST","volume":29611,"amount":1339311.4522000002,"timestamp":1768426638812},"delay":0,"floatShares":231836699,"shares":268112157,"eps":2.376525,"marketStatus":"盘后交易","change":1.15,"latestTime":"01-14 16:45:51 EST","open":44.28,"high":45.335,"low":44.02,"amount":76642641.890368,"amplitude":0.029832,"askPrice":45.25,"askSize":500,"bidPrice":45,"bidSize":130,"shortable":3,"etf":0,"ttmEps":2.376525,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1768438800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":955425600000,"exchange":"NASDAQ","adjPreClose":44.08,"preHourTrading":{"tag":"盘前","latestPrice":44.15,"preClose":44.08,"latestTime":"09:25 EST","volume":104,"amount":4653.699648,"timestamp":1768400720044},"postHourTrading":{"tag":"盘后","latestPrice":45.23,"preClose":45.23,"latestTime":"16:37 EST","volume":29611,"amount":1339311.4522000002,"timestamp":1768426638812},"volumeRatio":0.595136,"impliedVol":0.3675,"impliedVolPercentile":0.4622},"requestUrl":"/m/hq/s/EXEL","defaultTab":"news","newsList":[{"id":"1177048004","title":"伊克力西斯公布2025财年初步业绩，发布2026年财务指引并规划年度重点与里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1177048004","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177048004?lang=zh_cn&edition=full","pubTime":"2026-01-12 05:01","pubTimestamp":1768165274,"startTime":"0","endTime":"0","summary":"伊克力西斯（Exelixis）近日披露了其2025财年的初步财务数据，同时向市场提供了针对2026财年的财务业绩展望。此外，公司还详细阐述了2026年的核心战略重点与关键发展里程碑，为投资者勾勒出清晰的发展路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","EXEL","BK4139"],"gpt_icon":0},{"id":"1110382268","title":"伊克力西斯与Natera就结直肠癌药物Zanzalintinib的关键性III期试验Stellar-316达成合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1110382268","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110382268?lang=zh_cn&edition=full","pubTime":"2026-01-07 21:03","pubTimestamp":1767791008,"startTime":"0","endTime":"0","summary":"伊克力西斯与Natera公司宣布将开展战略合作，共同推进名为Stellar-316的III期关键性临床试验。该试验旨在评估Zanzalintinib针对结直肠癌患者的疗效与安全性，标志着双方在肿瘤治疗领域的重要布局。此次合作将整合伊克力西斯在靶向药物研发方面的优势与Natera在精准诊断技术领域的专长，为结直肠癌治疗探索新的可能性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2264538146.SGD","LU2065731478.USD","LU1988902786.USD","LU2324357040.USD","LU0345770993.USD","NTRA","LU0106261612.USD","LU2065170008.USD","LU2065171311.SGD","LU2065171402.SGD","LU1064131342.USD","LU0963586101.USD","LU0053671581.USD","EXEL","BK4532","LU0345770308.USD","LU0012050646.USD","LU2065169927.USD","BK4139"],"gpt_icon":0},{"id":"1123846009","title":"异动解读 | 分析师上调目标价，伊克力西斯盘中大涨5.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123846009","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123846009?lang=zh_cn&edition=full","pubTime":"2025-11-05 22:50","pubTimestamp":1762354206,"startTime":"0","endTime":"0","summary":"11月5日周三，生物制药公司伊克力西斯股价盘中大涨5.54%，引起投资者广泛关注。股价上涨主要受益于华尔街知名券商上调了该公司的目标价。根据最新消息，投资银行TD Cowen将伊克力西斯的目标价从44美元上调至51美元，上调幅度达15.9%。这一积极的分析师评级调整反映了市场对该公司未来发展前景的乐观预期，从而推动了股价的大幅上涨。伊克力西斯是一家专注于开发和商业化新型靶向癌症疗法的生物技术公司。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["EXEL"],"gpt_icon":0},{"id":"2580275033","title":"伊克力西斯盘中异动 早盘快速下挫6.83%报36.03美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2580275033","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580275033?lang=zh_cn&edition=full","pubTime":"2025-11-04 00:30","pubTimestamp":1762187402,"startTime":"0","endTime":"0","summary":"北京时间2025年11月04日00时30分，伊克力西斯股票出现波动，股价大幅跳水6.83%。截至发稿，该股报36.03美元/股，成交量144.606万股，换手率0.54%，振幅3.75%。机构评级方面，在所有21家参与评级的机构中，57%的券商给予买入建议，43%的券商给予持有建议，无券商给予卖出建议。伊克力西斯股票所在的生物技术行业中，整体跌幅为1.65%。伊克力西斯公司简介：Exelixis Inc是一家发现、研发并将癌症治疗方法商业化的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110400300294ec86d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110400300294ec86d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","BK4139","EXEL"],"gpt_icon":0},{"id":"1131577985","title":"Synox Therapeutics增聘领先商业化及企业发展专家，进一步强化董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1131577985","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131577985?lang=zh_cn&edition=full","pubTime":"2025-10-21 19:02","pubTimestamp":1761044561,"startTime":"0","endTime":"0","summary":"Synox Therapeutics增聘领先商业化及企业发展专家，进一步强化董事会，以继续推动公司的发展进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","LEGN","BK4588","BK4585","BK4532","AKRO","EXEL","BK4139"],"gpt_icon":0},{"id":"1179399318","title":"伊克力西斯公布III期Stellar-303关键试验的详细结果，评估Zanzalintinib与免疫检查点抑制剂联合治疗转移性结直肠癌，在2025年ESMO大会上展示并发表于《柳叶刀》","url":"https://stock-news.laohu8.com/highlight/detail?id=1179399318","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179399318?lang=zh_cn&edition=full","pubTime":"2025-10-20 14:31","pubTimestamp":1760941875,"startTime":"0","endTime":"0","summary":"伊克力西斯公布III期Stellar-303关键试验的详细结果，评估Zanzalintinib与免疫检查点抑制剂联合治疗转移性结直肠癌，在2025年ESMO大会上展示并发表于《柳叶刀》。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXEL","BK4139","BK4532"],"gpt_icon":0},{"id":"1191135420","title":"伊克力西斯：Cabometyx在晚期肺或胸腺神经内分泌肿瘤患者中相比安慰剂降低了81%的疾病进展或死亡风险","url":"https://stock-news.laohu8.com/highlight/detail?id=1191135420","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191135420?lang=zh_cn&edition=full","pubTime":"2025-10-18 15:10","pubTimestamp":1760771413,"startTime":"0","endTime":"0","summary":"伊克力西斯：Cabometyx在晚期肺或胸腺神经内分泌肿瘤患者中相比安慰剂降低了81%的疾病进展或死亡风险","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXEL","BK4532","BK4139"],"gpt_icon":0},{"id":"1141046996","title":"伊克力西斯公布2025年ESMO大会Cabometyx®（Cabozantinib）在晚期肺部和胸腺神经内分泌肿瘤的关键性3期临床试验亚组分析结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1141046996","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141046996?lang=zh_cn&edition=full","pubTime":"2025-10-18 15:05","pubTimestamp":1760771110,"startTime":"0","endTime":"0","summary":"伊克力西斯公布2025年ESMO大会Cabometyx®（Cabozantinib）在晚期肺部和胸腺神经内分泌肿瘤的关键性3期临床试验亚组分析结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4139","EXEL"],"gpt_icon":0},{"id":"1182725444","title":"伊克力西斯宣布任命Dana T. Aftab博士为研发执行副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=1182725444","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182725444?lang=zh_cn&edition=full","pubTime":"2025-08-30 05:48","pubTimestamp":1756504091,"startTime":"0","endTime":"0","summary":"伊克力西斯宣布任命Dana T. Aftab博士为研发执行副总裁","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EXEL","BK4532"],"gpt_icon":0},{"id":"2558697600","title":"伊克力西斯8月11日成交额为7943.63万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558697600","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558697600?lang=zh_cn&edition=full","pubTime":"2025-08-12 10:17","pubTimestamp":1754965052,"startTime":"0","endTime":"0","summary":"美东时间2025年8月11日，伊克力西斯成交额为7943.63万美元，成交额较昨日增加10.67%，当日成交量为211.72万股。伊克力西斯于2025年8月11日跌0.82%，报37.41美元，该股过去5个交易日涨1.63%，年初至今涨12.34%，过去60日跌16.22%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-08-11|7943.63万|10.67%|211.72万|#|2025-08-08|7177.89万|-27.76%|190.65万|#|2025-08-07|9936.08万|-2.40%|265.49万|#|2025-08-06|1.02亿|-28.17%|271.88万|#|2025-08-05|1.42亿|-12.11%|380.68万|Exelixis Inc是一家发现、研发并将癌症治疗方法商业化的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812101739a6e0a000&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812101739a6e0a000&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EXEL","BK4532","BK4139"],"gpt_icon":0},{"id":"2558850345","title":"伊克力西斯8月8日成交额为7177.89万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558850345","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558850345?lang=zh_cn&edition=full","pubTime":"2025-08-09 10:16","pubTimestamp":1754705774,"startTime":"0","endTime":"0","summary":"美东时间2025年8月8日，伊克力西斯成交额为7177.89万美元，成交额较昨日减少27.76%，当日成交量为190.65万股。伊克力西斯于2025年8月8日涨0.88%，报37.72美元，该股过去5个交易日涨1.23%，年初至今涨13.27%，过去60日涨2.08%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-08-08|7177.89万|-27.76%|190.65万|#|2025-08-07|9936.08万|-2.40%|265.49万|#|2025-08-06|1.02亿|-28.17%|271.88万|#|2025-08-05|1.42亿|-12.11%|380.68万|#|2025-08-04|1.61亿|-25.47%|438.32万|Exelixis Inc是一家发现、研发并将癌症治疗方法商业化的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809101622a47e2d40&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809101622a47e2d40&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EXEL","BK4532","BK4139"],"gpt_icon":0},{"id":"2557516866","title":"伊克力西斯8月7日成交额为9936.08万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557516866","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557516866?lang=zh_cn&edition=full","pubTime":"2025-08-08 10:15","pubTimestamp":1754619300,"startTime":"0","endTime":"0","summary":"美东时间2025年8月7日，伊克力西斯成交额为9936.08万美元，成交额较昨日减少2.40%，当日成交量为265.49万股。伊克力西斯于2025年8月7日跌0.85%，报37.39美元，该股过去5个交易日涨3.23%，年初至今涨12.28%，过去60日涨1.11%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-08-07|9936.08万|-2.40%|265.49万|#|2025-08-06|1.02亿|-28.17%|271.88万|#|2025-08-05|1.42亿|-12.11%|380.68万|#|2025-08-04|1.61亿|-25.47%|438.32万|#|2025-08-01|2.16亿|20.86%|580.68万|Exelixis Inc是一家发现、研发并将癌症治疗方法商业化的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808101508a6d9e87b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808101508a6d9e87b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","EXEL","BK4532"],"gpt_icon":0},{"id":"2557051582","title":"伊克力西斯8月6日成交额为1.02亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557051582","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557051582?lang=zh_cn&edition=full","pubTime":"2025-08-07 10:13","pubTimestamp":1754532832,"startTime":"0","endTime":"0","summary":"美东时间2025年8月6日，伊克力西斯成交额为1.02亿美元，成交额较昨日减少28.17%，当日成交量为271.88万股。伊克力西斯于2025年8月6日涨0.67%，报37.71美元，该股过去5个交易日涨2.31%，年初至今涨13.24%，过去60日涨4.26%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-08-06|1.02亿|-28.17%|271.88万|#|2025-08-05|1.42亿|-12.11%|380.68万|#|2025-08-04|1.61亿|-25.47%|438.32万|#|2025-08-01|2.16亿|20.86%|580.68万|#|2025-07-31|1.79亿|-6.57%|487.95万|Exelixis Inc是一家发现、研发并将癌症治疗方法商业化的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807101358a479d186&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807101358a479d186&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EXEL","BK4139","BK4532"],"gpt_icon":0},{"id":"2557349032","title":"伊克力西斯8月5日成交额为1.42亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557349032","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557349032?lang=zh_cn&edition=full","pubTime":"2025-08-06 10:10","pubTimestamp":1754446234,"startTime":"0","endTime":"0","summary":"美东时间2025年8月5日，伊克力西斯成交额为1.42亿美元，成交额较昨日减少12.11%，当日成交量为380.68万股。伊克力西斯于2025年8月5日涨1.77%，报37.46美元，该股过去5个交易日涨1.41%，年初至今涨12.49%，过去60日涨2.63%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-08-05|1.42亿|-12.11%|380.68万|#|2025-08-04|1.61亿|-25.47%|438.32万|#|2025-08-01|2.16亿|20.86%|580.68万|#|2025-07-31|1.79亿|-6.57%|487.95万|#|2025-07-30|1.92亿|-67.41%|514.81万|Exelixis Inc是一家发现、研发并将癌症治疗方法商业化的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806101039a6d5881a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806101039a6d5881a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EXEL","BK4139","BK4532"],"gpt_icon":0},{"id":"1133480010","title":"Exelixis 2025财年Q2业绩会总结及问答精华：CABOMETYX快速增长与Zanzalutinib新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1133480010","media":"业绩会速递","labels":["earningsCall"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133480010?lang=zh_cn&edition=full","pubTime":"2025-08-05 11:07","pubTimestamp":1754363235,"startTime":"0","endTime":"0","summary":"CABOMETYX净产品收入为5.18亿美元，临床试验销售额为60万美元，较上一季度的1200万美元大幅下降。我们预计2025年毛利率将接近30%。分析师和管理层的语气总体积极，管理层对CABOMETYX和zanzalutinib的未来表现充满信心。Exelixis在2025财年第二季度表现强劲，CABOMETYX在神经内分泌肿瘤市场的快速增长和zanzalutinib在结直肠癌中的积极数据为公司未来的发展奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"earningsCall","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXEL"],"gpt_icon":0},{"id":"2557356634","title":"伊克力西斯8月4日成交额为1.61亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557356634","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557356634?lang=zh_cn&edition=full","pubTime":"2025-08-05 10:09","pubTimestamp":1754359792,"startTime":"0","endTime":"0","summary":"美东时间2025年8月4日，伊克力西斯成交额为1.61亿美元，成交额较昨日减少25.47%，当日成交量为438.32万股。伊克力西斯于2025年8月4日跌1.21%，报36.81美元，该股过去5个交易日跌17.08%，年初至今涨10.54%，过去60日涨0.0%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-08-04|1.61亿|-25.47%|438.32万|#|2025-08-01|2.16亿|20.86%|580.68万|#|2025-07-31|1.79亿|-6.57%|487.95万|#|2025-07-30|1.92亿|-67.41%|514.81万|#|2025-07-29|5.88亿|98.97%|1574.43万|Exelixis Inc是一家发现、研发并将癌症治疗方法商业化的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805101001a47582ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805101001a47582ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","EXEL","BK4532"],"gpt_icon":0},{"id":"2556429128","title":"伊克力西斯8月1日成交额为2.16亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2556429128","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556429128?lang=zh_cn&edition=full","pubTime":"2025-08-02 10:09","pubTimestamp":1754100551,"startTime":"0","endTime":"0","summary":"美东时间2025年8月1日，伊克力西斯成交额为2.16亿美元，成交额较昨日增加20.86%，当日成交量为580.68万股。伊克力西斯于2025年8月1日涨2.87%，报37.26美元，该股过去5个交易日跌18.29%，年初至今涨11.89%，过去60日涨1.09%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-08-01|2.16亿|20.86%|580.68万|#|2025-07-31|1.79亿|-6.57%|487.95万|#|2025-07-30|1.92亿|-67.41%|514.81万|#|2025-07-29|5.88亿|98.97%|1574.43万|#|2025-07-28|2.95亿|81.96%|661.56万|Exelixis Inc是一家发现、研发并将癌症治疗方法商业化的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250802100915a6cead8f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250802100915a6cead8f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","BK4139","EXEL"],"gpt_icon":0},{"id":"1127801763","title":"异动解读 | 伊克力西斯发布季度财报后盘中大涨5.05%，超出市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1127801763","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127801763?lang=zh_cn&edition=full","pubTime":"2025-08-02 02:25","pubTimestamp":1754072700,"startTime":"0","endTime":"0","summary":"今日盘中，生物制药公司伊克力西斯股价大涨5.05%，引起市场广泛关注。这一涨势与公司刚刚发布的2025财年第二季度财报密切相关。根据财报显示，伊克力西斯第二季度净利润为1.85亿美元，同比下降18.14%；营业收入为5.68亿美元，同比下降10.83%；每股基本收益为0.68美元。值得注意的是，截至8月2日，有19家机构对伊克力西斯给出了目标价预测。平均目标价为45.11美元，最低36.00美元，最高60.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["EXEL"],"gpt_icon":0},{"id":"2555966620","title":"伊克力西斯7月29日成交额为5.88亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555966620","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555966620?lang=zh_cn&edition=full","pubTime":"2025-07-30 10:14","pubTimestamp":1753841660,"startTime":"0","endTime":"0","summary":"美东时间2025年7月29日，伊克力西斯成交额为5.88亿美元，成交额较昨日增加98.97%，当日成交量为1574.43万股。伊克力西斯于2025年7月29日跌16.78%，报36.94美元，该股过去5个交易日跌16.93%，年初至今涨10.93%，过去60日跌5.01%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-07-29|5.88亿|98.97%|1574.43万|#|2025-07-28|2.95亿|81.96%|661.56万|#|2025-07-25|1.62亿|64.85%|357.30万|#|2025-07-24|9850.09万|-7.35%|219.16万|#|2025-07-23|1.06亿|4.57%|235.36万|Exelixis Inc是一家发现、研发并将癌症治疗方法商业化的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730101427a6c8c0f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730101427a6c8c0f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","BK4139","EXEL"],"gpt_icon":0},{"id":"1125267960","title":"异动解读 | 业绩不及预期，伊克力西斯盘中大跌15.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=1125267960","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125267960?lang=zh_cn&edition=full","pubTime":"2025-07-29 21:37","pubTimestamp":1753796223,"startTime":"0","endTime":"0","summary":"生物制药公司伊克力西斯今日盘中大跌15.50%，引发市场广泛关注。这一显著跌幅主要源于公司近期公布的第二季度财报未能完全达到市场预期。根据伊克力西斯最新发布的财报显示，截至6月30日的季度调整后每股收益为0.65美元，虽然高于分析师平均预期的0.56美元，但低于去年同期的0.77美元。值得注意的是，在此次财报公布之前，伊克力西斯的股价表现相当强劲，今年迄今为止已上涨36.9%。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["EXEL"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.exelixis.com","stockEarnings":[{"period":"1week","weight":0.0092},{"period":"1month","weight":0.0783},{"period":"3month","weight":0.1012},{"period":"6month","weight":-0.0176},{"period":"1year","weight":0.2487},{"period":"ytd","weight":0.0057}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":0.0176},{"period":"3month","weight":0.043},{"period":"6month","weight":0.1047},{"period":"1year","weight":0.1933},{"period":"ytd","weight":0.0174}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Exelixis, Inc.是一家生物科技公司，致力于研发癌症小分子治疗。公司于1994年11月在特拉华州注册为Exelixis制药股份有限公司，并于2000年2月改为Exelixis股份有限公司。公司的资源、研发、生产专注于COMETRIQ（卡博替尼胶囊，公司全资的多靶点受体酪氨酸激酶抑制剂）。公司目标是将COMETRIQ发展成一项主要的特许肿瘤经营产品，认为COMETRIQ治疗恶化、转移的MTC的批准给实现该目标、树立商业地位提供了一个机会。","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.017319},{"month":2,"riseRate":0.48,"avgChangeRate":0.021275},{"month":3,"riseRate":0.52,"avgChangeRate":-0.010734},{"month":4,"riseRate":0.56,"avgChangeRate":0.053554},{"month":5,"riseRate":0.461538,"avgChangeRate":0.003414},{"month":6,"riseRate":0.576923,"avgChangeRate":0.026268},{"month":7,"riseRate":0.538462,"avgChangeRate":0.042251},{"month":8,"riseRate":0.461538,"avgChangeRate":-0.009406},{"month":9,"riseRate":0.461538,"avgChangeRate":-0.037422},{"month":10,"riseRate":0.538462,"avgChangeRate":-0.005954},{"month":11,"riseRate":0.615385,"avgChangeRate":0.062892},{"month":12,"riseRate":0.615385,"avgChangeRate":0.051791}],"exchange":"NASDAQ","name":"伊克力西斯","nameEN":"Exelixis"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"伊克力西斯(EXEL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供伊克力西斯(EXEL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"伊克力西斯,EXEL,伊克力西斯股票,伊克力西斯股票老虎,伊克力西斯股票老虎国际,伊克力西斯行情,伊克力西斯股票行情,伊克力西斯股价,伊克力西斯股市,伊克力西斯股票价格,伊克力西斯股票交易,伊克力西斯股票购买,伊克力西斯股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"伊克力西斯(EXEL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供伊克力西斯(EXEL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}